- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Cyclerion Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 18.04. | Cyclerion Therapeutics, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 02.04. | Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? | 7 | Barchart.com | ||
| 02.04. | Alzheimer's biotech Korsana to go public via reverse merger | - | pharmaphorum | ||
| 01.04. | Korsana Biosciences and Cyclerion Therapeutics to Merge, Operate Under Korsana Name | 3 | Contract Pharma | ||
| 01.04. | Cyclerion Therapeutics: $380 Million Financing To Merge With Korsana Biosciences And Advance Alzheimer's Pipeline | 1 | pulse2.com | ||
| CYCLERION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.04. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public | 3 | FierceBiotech | ||
| 01.04. | Morning Market Movers: Cyclerion Therapeutics, Binah Capital Group, Target Hospitality Corp., nCino See Big Swings | 795 | AFX News | WASHINGTON COUNTY (dpa-AFX) - At 8:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before... ► Artikel lesen | |
| 01.04. | Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. Announce Merger Agreement | 141 | Business Wire | Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases
Korsana's lead program KRSA-028 is a next-generation... ► Artikel lesen | |
| 16.03. | Korsana Biosciences Taps Dr. Mark Vignola as CFO | 1 | Contract Pharma | ||
| 22.02. | Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer's Drug | 1 | MedCity News | ||
| 18.02. | Korsana Biosciences Raises $175M in Funding | 1 | FinSMEs | ||
| 17.02. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.02. | Cyclerion receives FDA feedback on depression treatment development | 6 | Investing.com | ||
| 06.01. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | Cyclerion-Aktie mit massivem Kurssprung nach strategischer Kooperation mit Medsteer | 9 | Investing.com Deutsch | ||
| 05.01. | Cyclerion und Medsteer kooperieren bei der Entwicklung einer neuartigen Depressionstherapie | 1 | Investing.com Deutsch | ||
| 05.01. | Cyclerion partners with Medsteer to advance depression treatment platform | 1 | Investing.com | ||
| 05.01. | Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression | 167 | GlobeNewswire (Europe) | - Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer - - Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 3,470 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| BEAM THERAPEUTICS | 29,560 | +0,03 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,687 | -1,36 % | Outlook Therapeutics, Inc.: Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg) | ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA (bevacizumab-vikg... ► Artikel lesen | |
| CORMEDIX | 6,920 | -2,56 % | CorMedix, Inc.: Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | ? Q1 2026 Net Revenue of $127.4 million ? ? Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ? - Company raises FY 2026 Revenue and Adjusted EBITDA Guidance - ? Conference Call... ► Artikel lesen | |
| REPLIMUNE | 8,526 | -0,81 % | Replimune Group, Inc.: Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented... ► Artikel lesen | |
| ABSCI | 5,935 | -0,08 % | BTIG initiates Absci stock with buy rating on AI drug platform | ||
| MATINAS BIOPHARMA | 0,790 | +2,49 % | Matinas BioPharma Holdings, Inc.: Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards | BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE American: MTNB) announced today that on April 2, 2026, it received a notice (the "Notice")... ► Artikel lesen | |
| CINGULATE | 4,900 | +0,41 % | ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection | ||
| STRUCTURE THERAPEUTICS | 37,500 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| NURIX THERAPEUTICS | 15,470 | -0,06 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| BIOXYNE | 0,060 | +100,00 % | Millionen-Liefervertrag für den deutschen Markt: Bioxyne Limited meldet operativen Durchbruch | ||
| SILO PHARMA | 6,130 | 0,00 % | Silo Pharma kündigt Aktienzusammenlegung im Verhältnis 1:15 an | ||
| COMPASS THERAPEUTICS | 2,090 | -0,48 % | Stifel reiterates Compass Therapeutics stock rating on ASCO data | ||
| MAXCYTE | 1,020 | 0,00 % | MaxCyte, Inc: MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance | Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 25,050 | -0,04 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen |
CYCLERION THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,010 (+0,33 %) liegt der Kurs bei 3,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYCLERION THERAPEUTICS INC finden Sie auf Wallstreet Online.